New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization

Contributed by: Business Wire

Logo

Tags

Infectious Diseases

Pharmaceutical

Health

Clinical Trials

Dengue Vaccine, QDENGA

More Like This

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults

ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

UK Government Strengthens Vaccine Partnership with CSL Seqirus, Introducing World-First Flu vaccine (aTIVc) and Extending Health Security Pandemic Agreement

Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress